Thomas Van Blarcom

1.4k total citations
27 papers, 814 citations indexed

About

Thomas Van Blarcom is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Thomas Van Blarcom has authored 27 papers receiving a total of 814 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 13 papers in Oncology and 11 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Thomas Van Blarcom's work include CAR-T cell therapy research (13 papers), Monoclonal and Polyclonal Antibodies Research (11 papers) and Viral Infectious Diseases and Gene Expression in Insects (10 papers). Thomas Van Blarcom is often cited by papers focused on CAR-T cell therapy research (13 papers), Monoclonal and Polyclonal Antibodies Research (11 papers) and Viral Infectious Diseases and Gene Expression in Insects (10 papers). Thomas Van Blarcom collaborates with scholars based in United States, Germany and Switzerland. Thomas Van Blarcom's co-authors include George Georgiou, Yariv Mazor, Brent L. Iverson, Robert L. Mabry, Javier Chaparro‐Riggers, Zea Melton, Arvind Rajpal, Jaume Pons, Kevin C. Lindquist and Yasmina Abdiche and has published in prestigious journals such as Nature Communications, Blood and Nature Biotechnology.

In The Last Decade

Thomas Van Blarcom

27 papers receiving 783 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas Van Blarcom United States 15 503 421 239 222 79 27 814
Gertrudis Rojas Cuba 17 440 0.9× 318 0.8× 126 0.5× 190 0.9× 70 0.9× 38 680
Julia Hambach Germany 8 281 0.6× 345 0.8× 199 0.8× 221 1.0× 57 0.7× 13 611
Karen Silence Belgium 5 523 1.0× 654 1.6× 103 0.4× 281 1.3× 38 0.5× 6 884
Fabrice Le Gall Germany 16 495 1.0× 650 1.5× 356 1.5× 356 1.6× 46 0.6× 20 998
Mikaela Friedman Sweden 14 461 0.9× 496 1.2× 229 1.0× 78 0.4× 71 0.9× 24 800
Lena Danielsson Sweden 16 683 1.4× 762 1.8× 125 0.5× 407 1.8× 40 0.5× 29 1.1k
Irene Ni United States 11 347 0.7× 379 0.9× 166 0.7× 356 1.6× 30 0.4× 15 743
Anneke W. Reurs Netherlands 11 479 1.0× 441 1.0× 245 1.0× 251 1.1× 21 0.3× 16 793
Ralf J. Hosse Switzerland 12 316 0.6× 289 0.7× 181 0.8× 210 0.9× 28 0.4× 16 675
Tae Hyun Kang South Korea 13 561 1.1× 562 1.3× 118 0.5× 245 1.1× 29 0.4× 18 805

Countries citing papers authored by Thomas Van Blarcom

Since Specialization
Citations

This map shows the geographic impact of Thomas Van Blarcom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Van Blarcom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Van Blarcom more than expected).

Fields of papers citing papers by Thomas Van Blarcom

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Van Blarcom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Van Blarcom. The network helps show where Thomas Van Blarcom may publish in the future.

Co-authorship network of co-authors of Thomas Van Blarcom

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Van Blarcom. A scholar is included among the top collaborators of Thomas Van Blarcom based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Van Blarcom. Thomas Van Blarcom is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Taubmann, Jule, Christina Bergmann, Johannes Knitza, et al.. (2025). Exploring CAR T-Cell Dynamics: Balancing Potent Cytotoxicity and Controlled Inflammation in CAR T-Cells Derived from Systemic Sclerosis and Myositis Patients. International Journal of Molecular Sciences. 26(2). 467–467. 3 indexed citations
2.
Kwong, Brandon, Joseph Banuelos, Petro Starokadomskyy, et al.. (2024). POS0462 PRECLINICAL DEVELOPMENT OF KYV-201, AN INVESTIGATIONAL ALLOGENEIC ANTI-CD19 CAR T CELL FOR THE TREATMENT OF AUTOIMMUNE DISEASE. Annals of the Rheumatic Diseases. 83. 1129–1130. 2 indexed citations
3.
Tacheva-Grigorova, Silvia K., Janette Sutton, Zea Melton, et al.. (2023). Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer. Clinical Cancer Research. 29(5). 971–985. 31 indexed citations
4.
Lin, Regina, Janette Sutton, Trevor Bentley, et al.. (2023). Constitutive Turbodomains enhance expansion and antitumor activity of allogeneic BCMA CAR T cells in preclinical models. Science Advances. 9(31). eadg8694–eadg8694. 3 indexed citations
5.
Panowski, Siler H., Nguyêñ Duy Tân, Silvia K. Tacheva-Grigorova, et al.. (2022). Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma. Cancer Research. 82(14). 2610–2624. 57 indexed citations
6.
Lin, Regina, Andrew R. Nager, Spencer Park, et al.. (2022). Design and Validation of Inducible TurboCARs with Tunable Induction and Combinatorial Cytokine Signaling. Cancer Immunology Research. 10(9). 1069–1083. 6 indexed citations
7.
Dominik, Pawel K., Sheng Ding, Wenjing Yang, et al.. (2021). Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity. Journal for ImmunoTherapy of Cancer. 9(10). e003464–e003464. 96 indexed citations
8.
Park, Spencer, Edward Pascua, Kevin C. Lindquist, et al.. (2021). Direct control of CAR T cells through small molecule-regulated antibodies. Nature Communications. 12(1). 710–710. 38 indexed citations
9.
Sommer, Cesar, Trevor Bentley, Janette Sutton, et al.. (2019). Off-the-shelf AlloCAR T™ cells targeting BCMA for the treatment of multiple myeloma. Clinical Lymphoma Myeloma & Leukemia. 19(10). e24–e24. 3 indexed citations
10.
Blarcom, Thomas Van, Andrea Rossi, Davide Foletti, et al.. (2018). Epitope Mapping Using Yeast Display and Next Generation Sequencing. Methods in molecular biology. 1785. 89–118. 8 indexed citations
11.
Panowski, Siler H., Tracy C. Kuo, Amy Chen, et al.. (2016). Preclinical Evaluation of a Potent Anti-Bcma CD3 Bispecific Molecule for the Treatment of Multiple Myeloma. Blood. 128(22). 383–383. 19 indexed citations
12.
13.
Blarcom, Thomas Van, Andrea Rossi, Davide Foletti, et al.. (2014). Precise and Efficient Antibody Epitope Determination through Library Design, Yeast Display and Next-Generation Sequencing. Journal of Molecular Biology. 427(6). 1513–1534. 50 indexed citations
14.
Bolles, Meagan, Eric Donaldson, Thomas Van Blarcom, et al.. (2012). Increased Antibody Affinity Confers Broad In Vitro Protection against Escape Mutants of Severe Acute Respiratory Syndrome Coronavirus. Journal of Virology. 86(17). 9113–9121. 27 indexed citations
15.
Zhai, Wenwu, Jacob Glanville, Markus Fuhrmann, et al.. (2011). Synthetic Antibodies Designed on Natural Sequence Landscapes. Journal of Molecular Biology. 412(1). 55–71. 70 indexed citations
16.
Mazor, Yariv, Thomas Van Blarcom, Sean M. Carroll, & George Georgiou. (2010). Selection of full‐length IgGs by tandem display on filamentous phage particles and Escherichia coli fluorescence‐activated cell sorting screening. FEBS Journal. 277(10). 2291–2303. 33 indexed citations
17.
18.
Davidson, Eric A., Thomas Van Blarcom, Matthew Levy, & Andrew D. Ellington. (2009). EMULSION BASED SELECTION OF T7 PROMOTERS OF VARYING ACTIVITY. WORLD SCIENTIFIC eBooks. 433–443. 14 indexed citations
19.
Mazor, Yariv, Thomas Van Blarcom, Brent L. Iverson, & George Georgiou. (2008). E-clonal antibodies: selection of full-length IgG antibodies using bacterial periplasmic display. Nature Protocols. 3(11). 1766–1777. 39 indexed citations
20.
Blarcom, Thomas Van, et al.. (2007). A scFv Antibody Mutant Isolated in a Genetic Screen for Improved Export via the Twin Arginine Transporter Pathway Exhibits Faster Folding. Journal of Molecular Biology. 369(3). 631–639. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gertrudis Rojas Breakdown of academic impact, for papers by Julia Hambach Breakdown of academic impact, for papers by Karen Silence Breakdown of academic impact, for papers by Fabrice Le Gall Breakdown of academic impact, for papers by Mikaela Friedman Breakdown of academic impact, for papers by Lena Danielsson Breakdown of academic impact, for papers by Irene Ni Breakdown of academic impact, for papers by Anneke W. Reurs Breakdown of academic impact, for papers by Ralf J. Hosse Breakdown of academic impact, for papers by Tae Hyun Kang
Rankless by CCL
2026